



## Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 04, 2026

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- [Relay Therapeutics, Inc.](https://www.relaytx.com) (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 10:30 a.m. ET.

The fireside chats will be webcast live and may be accessed through Relay Therapeutics' website under Events in the News & Events section through the following link: <https://ir.relaytx.com/news-events/events-presentations>. An archived replay of the webcast will be available for up to 30 days following the event.

### About Relay Therapeutics

Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Relay's Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The company's lead clinical asset, zovegalisib, is the first pan-mutant selective PI3K $\alpha$  inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3K $\alpha$ -driven vascular anomalies. Relay's pipeline also includes programs for NRAS-driven solid tumors and Fabry disease. For more information, please visit [www.relaytx.com](http://www.relaytx.com) or [follow us on LinkedIn](#).

### Contact:

Pete Rahmer

[prahmer@relaytx.com](mailto:prahmer@relaytx.com)

### Media:

Dan Budwick

1AB

973-271-6085

[dan@1abmedia.com](mailto:dan@1abmedia.com)